NovoCure Limited

NasdaqGS NVCR

NovoCure Limited Cash and Short-Term Investments for the year ending December 31, 2023: USD 910.62 M

NovoCure Limited Cash and Short-Term Investments is USD 910.62 M for the year ending December 31, 2023, a -6.07% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

NovoCure Limited Cash and Short-Term Investments for the year ending December 31, 2022 was USD 969.42 M, a 3.38% change year over year.
NovoCure Limited Cash and Short-Term Investments for the year ending December 31, 2021 was USD 937.70 M, a 11.29% change year over year.
NovoCure Limited Cash and Short-Term Investments for the year ending December 31, 2020 was USD 842.58 M, a 158.39% change year over year.
NovoCure Limited Cash and Short-Term Investments for the year ending December 31, 2019 was USD 326.09 M, a 32.62% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqGS: NVCR

NovoCure Limited

CEO	Mr. Asaf Danziger
IPO Date	Oct. 1, 2015
Location	Jersey
Headquarters	No. 4 The Forum
Employees	1,453
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Key trends

Past 5 years